Seattle biotech Silverback Therapeutics raises $85M, just six months after raising $78.5M

Silverback Therapeutics announced that it received $85 million in Series C funding, following closely on the heels of a $78.5 million funding round in March of this year. The capital will go towards advancing its ImmunoTAC programs, currently being developed to use the body’s immune system to fight cancer cells.  

READ THE STORY at GeekWire »